Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
Is there a role of prophylactic aspirin in patients with incidental findings of aortic atherosclerosis but no history CAD or CVA?
Related Questions
Do you routinely recommend adding a nonstatin lipid-lowering agent for patients with ACS who are on maximally tolerated statin therapy and have an LDL-C between 55 and 69 mg/dL?
How soon after initiating oral anticoagulation therapy for atrial fibrillation can it be interrupted for surgery or procedures?
Do you recommend starting a statin in patients above 75 years old with diabetes but no known ASCVD?
What patient factors do you consider when selecting between a small interfering RNA, like inclisiran, and PCSK9 inhibitors in patients with recent acute coronary syndrome?
What are your preferred lipid-lowering agents and target LDL reduction goal following initiation of therapy for patients with familial hyperlipidemia without underlying CAD?
What is a reasonable timeline for a left heart catheterization in a patient with newly diagnosed severe LV systolic dysfunction of unclear etiology and without an ACS presentation?
What are your top takeaways from ACC 2025?
How do you approach the management of extremely low LDL levels in older adult patients receiving statin therapy for primary prevention of cardiovascular disease?
What are your thoughts on the results from the AQUATIC trial which showed that the addition of aspirin daily + oral anticoagulation in patients > 6 months from PCI and with high atherothrombotic risk was associated with a higher risk of death, MI, stroke, coronary revascularization and acute limb ischemia, compared to oral anticoagulation alone?
What is your approach to the management of incidentally elevated HDL levels in isolation and is there any utility for further ASCVD risk stratification and/or genetic testing for lipid disorders?
